YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
ApexOnco Front Page
Recent articles
While Sutro shows why it’s shelved luvelta-T.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Could a new ADC project distract attention away from evorpacept?
